Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Sutro Biopharma, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 119 | 1 | 116 | −2 |
| Shares | 50.0M | 11.2K | 53.5M | +3.54M (+7.1%) |
| Value | $403.7M | $90.5K | $247.5M | −$156.1M (−38.7%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Sutro Biopharma, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 157,838 | $729.2K | 0.00% |
| Simplify Asset Management Inc. | 120,000 | $554.4K | 0.10% |
| DAFNA Capital Management LLC | 84,700 | $391.3K | 0.12% |
| Putnam Investments LLC | 71,142 | $328.7K | 0.00% |
| Adage Capital Partners GP, L.L.C. | 55,720 | $257.4K | 0.00% |
| Algert Global LLC | 45,540 | $210.4K | 0.01% |
| Tejara Capital Ltd | 44,483 | $205.5K | 0.11% |
| Profund Advisors LLC | 40,247 | $185.9K | 0.01% |
| Qube Research & Technologies Ltd | 39,632 | $183.1K | 0.00% |
| Virtus Investment Advisers, Inc. | 28,274 | $130.6K | 0.09% |
| Squarepoint Ops LLC | 12,953 | $59.8K | 0.00% |
| E Fund Management Co., Ltd. | 12,245 | $57.0K | 0.00% |
| Virtus Fund Advisers, LLC | 4,412 | $20.4K | 0.14% |
| Values First Advisors, Inc. | 3,942 | $18.2K | 0.01% |
| Point72 Middle East FZE | 3,281 | $15.2K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 3,144 | $14.5K | 0.00% |
| Bogart Wealth, LLC | 500 | $2.31K | 0.00% |
| Signaturefd, LLC | 124 | $573 | 0.00% |
Sold out (20)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 790,600 | $6.39M |
| Endurant Capital Management LP | 281,895 | $2.28M |
| Caas Capital Management LP | 115,981 | $937.1K |
| New York Life Investment Management LLC | 69,012 | $557.6K |
| Connor, Clark & Lunn Investment Management Ltd. | 65,227 | $527.0K |
| Jump Financial, LLC | 42,600 | $344.2K |
| Corton Capital Inc. | 32,058 | $259.0K |
| Pura Vida Investments, LLC | 31,409 | $253.8K |
| Delphia (USA) Inc. | 29,456 | $238.0K |
| Bailard, Inc. | 20,300 | $164.0K |
| Walleye Capital LLC | 18,060 | $145.9K |
| Balyasny Asset Management LLC | 17,610 | $142.3K |
| Jane Street Group, LLC | 17,553 | $141.8K |
| Lazard Asset Management LLC | 15,868 | $128.0K |
| Two Sigma Securities, LLC | 15,567 | $125.8K |
| Quantbot Technologies LP | 14,712 | $118.9K |
| Allworth Financial LP | 41 | $331 |
| Credit Suisse AG | 2 | $16 |
| CWM, LLC | 33 | $0 |
| Rockefeller Capital Management L.P. | 93 | $0 |
Not filed for Q1 2023 yet (1)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Personal Capital Advisors Corp | 11,202 | $90.5K |